Curiox BioSystems Co

Curiox BioSystems Co FCF/Debt

The Free Cash Flow to Debt Ratio of Curiox BioSystems Co (445680.KQ) as of Oct 26, 2026 is -867.81 %. In the previous year, Free Cash Flow to Debt Ratio was -2,770.81 % — a change of -68.68% (higher).

FCF/Debt

-867.81 %

YoY

-68.68%

Last updated:

Free Cash Flow to Debt Ratio of Curiox BioSystems Co is 2023 -867.81 % . Free Cash Flow to Debt Ratio of Curiox BioSystems Co was 2022 -2,770.81 % . It decreases by -68.68% higher compared to the previous year.

The Curiox BioSystems Co FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2021
-32.82 KRW
Jan 1, 2022
-2,770.81 KRW
Jan 1, 2023
-867.81 KRW
The Curiox BioSystems Co FCF/Debt history
YEARFCF/DebtYoY
-867.81 %-68.68%
-2,770.81 %+8,341.93%
-32.82 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Curiox BioSystems Co Stock analysis

What does Curiox BioSystems Co do? Curiox BioSystems Co Ltd generates revenue through the manufacture and sale of automation equipment and consumables for cell analysis processes. The company offers cell pretreatment automation devices, washing machines, and plates, alongside high-capacity adapters, strip spacers, and buffer exchanger products. These products are sold to customers in the Life Sciences Tools & Services industry, primarily within the Korean market. The firm's focus on automation solutions for cell analysis drives its product portfolio and customer base. The company's product lines include cell pretreatment automation devices, washing machines, plates, high-capacity adapters, strip spacers, and buffer exchanger products. These items are designed for use in cell analysis processes, targeting clients who require efficient and precise laboratory equipment. The sales of these specialized tools form the core of Curiox BioSystems' revenue streams. Curiox BioSystems operates within the Life Sciences Tools & Services industry, focusing on providing automation solutions for cell analysis. Its products are manufactured and sold directly to end-users in the life sciences sector, including research institutions and laboratories. The company's revenue is derived from the direct sale of its equipment and consumables without intermediaries. Curiox BioSystems Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Curiox BioSystems Co stock

Free Cash Flow to Debt Ratio of Curiox BioSystems Co is -867.81 % in 2023.

Free Cash Flow to Debt Ratio of Curiox BioSystems Co changed from -2,770.81 % to -867.81 %, representing a -68.68% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Curiox BioSystems Co since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Curiox BioSystems Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Curiox BioSystems Co

All Key Metrics — Curiox BioSystems Co